BioSpace News Archive

iZafe Group AB - hereby announces that Zafe Care Systems is ordering 50 Dosell and is now initiating offensive marketing activities to bring the pharmaceutical robot to market.

Appia Bio, Inc. today announced the appointment of Irving Weissman , MD, and Mark Exley, PhD, to its Scientific Advisory Board.

Heru Selected to Present Among Titans in Healthcare, Medicine, Science and Business at the 10th Annual Forbes Healthcare Summit.

AMRA Medical, announced today that AMRA has received MDEL (Medical Device Establishment Licence) licensing and is permitted to distribute AMRA® MAsS Scan (Muscle Assessment Score) in Canada.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces the first five patients have been treated in the INSIGHT-003 study.

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021.

The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that GBT will provide a grant of $400,000 to the ASH RC in support of the ASH RC Data Hub Sickle Cell Disease (SCD) program.

Meridian Bioscience, Inc. announced today that Bryan Baldasare , Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31 , 2021.

Blue Cross Blue Shield of Massachusetts (Blue Cross) today announced it will contribute $25 million to support local health care organizations in their efforts to eliminate racial and ethnic inequities in care.

Combined company will operate as EOM Pharmaceuticals Holdings, Inc. advancing a pipeline of novel immunomodulatory agents including EOM613 currently in clinical trials in Brazil as a potential treatment for severely ill COVID-19 patients.